quartzbio™

The Hidden Costs of Fragmented Sample Data in Clinical Trials

Turn sample & biomarker data into a decision-ready asset that accelerates timelines, reduces risk, and scales operations—without adding headcount.

Every Day Your Sample Data Is Fragmented, You're Paying for It

Clinical trial sponsors spend millions collecting and analyzing patient samples—yet critical drug development decisions are still slowed by disconnected systems, manual reconciliation, and late-stage data surprises.

If your teams are reconciling spreadsheets, chasing emails, or querying across vendors, you're paying for it in time, money, and risk.

What this costs:

Trial timeline delays

- **$40-$50k per day** in Phase II/III
- **$540k - $856k per day** in unrealized revenue

Regulatory exposure increases

- **$500–$600 per lost sample,** before downstream impact
- **$1.5M average loss** per compromised study due to unreliable data
- **~$287K cost per trial** from protocol deviations

Operations teams hit scale limits

- **Annual labor drag: ~$740,000**
- **$84K–$710K+ per trial** just to resolve queries - excluding timeline impact

Decision confidence erodes

- **Disconnected** PK/PD and biomarker data
- **Late, inconclusive, or wrong** go/no-go decisions
- **Conflicting dashboards** across teams with no true source of truth

*sources:
(1) Cost of Delay Day in Drug Development
(2) Employer Costs for Employee Compensation
(3) The True Cost of Unusable Samples in Pharma Research
(4) Mitigating Risks for Biospecimen Management in Clinical Trials
(5) Impact of Regulatory Audit Findings on Trial Timelines and Approvals

The QuartzBio Difference

From Fragmented Data to Decision-Ready Intelligence

QuartzBio Sample Intelligence creates a connected, AI-driven sample data ecosystem that continuously monitors, reconciles, and governs sample and biomarker data across vendors and systems - so leaders get speed and confidence.

What this means:

One trusted source of truth across EDC, labs, and vendors

82–85% reduction
in manual sample-related work

Continuously detect missing and out-of-protocol samples

100% detection
of missing samples

$50K–$250K per study
saved by avoiding protocol deviations

Built-in consent, chain of custody, and audit readiness

98% reduction
in reconciliation effort

92% reduction
in query tracking time

Real-time insights without manual data wrangling

Double study capacity
without adding headcount

$235K–$372K savings
per Phase II–III trial

See what your sample data is really costing you.

Schedule a 30-minute executive walkthrough to quantify timeline risk, labor drag, and savings potential across your portfolio.

CONTACT US